Psoriasis and infection. A clinical practice narrative
- 5 August 2018
- journal article
- review article
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 60 (2) , 91-98
Abstract
The Australasian Psoriasis Collaboration has developed a clinical practice narrative with respect to the relationship between psoriasis, its treatment and infection. The cutaneous microbiome of patients with psoriasis is different to those without psoriasis, although the significance of this is unclear. Whilst a wide range of microorganisms has been associated with psoriasis (including β‐haemolytic streptococci, Staphylococcus aureus, Porphyromonas gingivalis, Candida albicans, Chlamydia psittaci, human immunodeficiency virus and hepatitis C virus), there is limited evidence that antimicrobial therapy is of direct benefit in preventing flares of psoriasis. Psoriasis is independently associated with an increased risk of serious infection, but the absolute risk is low. The risk of serious infections is further increased with immune‐modulatory treatments. The decision whether to, and when to, stop or resume immune‐modulatory treatment after a serious infection has occurred depends on risk assessment for that patient, taking into account the infection being treated, the risk of recurrent infection, any interventions that can modify the risk and the need for psoriasis control. Live vaccines (e.g. MMR, varicella, zoster and yellow fever) are generally contraindicated in patients with psoriasis on immune‐modulatory agents, but this depends on the degree of immune suppression and individual risk factors. Wound healing in psoriasis is normal. Treatment with infliximab, adalimumab, etanercept, methotrexate and ciclosporin can safely be continued through low‐risk surgical procedures. For moderate‐ and high‐risk surgeries, a case‐by‐case approach should be taken based on the patient's individual risk factors and comorbidities.Keywords
Funding Information
- AbbVie
- Amgen
- Biogen Idec
- Celgene
- Galderma
- Novartis
- Regeneron Pharmaceuticals
- Wyeth
This publication has 59 references indexed in Scilit:
- The association of sore throat and psoriasis might be explained by histologically distinctive tonsils and increased expression of skin-homing molecules by tonsil T cellsClinical and Experimental Immunology, 2013
- Profile of patients with psoriasis associated with hepatitis C virus infectionThe Journal of Dermatology, 2013
- Detection of DNA ofChlamydophila psittaciin subjects with psoriasis: a casual or a causal link?British Journal of Dermatology, 2012
- Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 DiseasePLOS Genetics, 2012
- Increased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohortJournal of the American Academy of Dermatology, 2011
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Annals of the Rheumatic Diseases, 2010
- Psoriasis Associated with Hepatitis C but Not with Hepatitis BDermatology, 2010
- β-Papillomaviruses and psoriasis: an intra-patient comparison of human papillomavirus carriage in skin and hairBritish Journal of Dermatology, 2008
- Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjectsJournal of the American Academy of Dermatology, 2005
- A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasisBritish Journal of Dermatology, 2001